Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection

  • Yu-Shan Huang
  • Hsin-Yun Sun
  • Sui-Yuan Chang
  • Yu-Chung Chuang
  • Aristine Cheng
  • Sung-Hsi Huang
  • Yi-Chia Huang
  • Guan-Jhou Chen
  • Kuan-Yin Lin
  • Yi-Ching Su
  • Wen-Chun Liu
  • Chien-Ching HungEmail author
Original Article



Data regarding the durability of HBV viral suppression with combination antiretroviral therapy (cART) containing tenofovir disoproxil fumarate (TDF) combined with lamivudine (3TC) or emtricitabine (FTC) in HIV/HBV-coinfected patients are scarce in hyperendemic areas of chronic HBV infection.


Between 2004 and 2016, HIV/HBV-coinfected Taiwanese with available baseline HBV DNA load were retrospectively reviewed. Determinations of plasma HBV DNA load, HBV serologic markers (HBsAg, anti-HBs, HBeAg, and anti-HBe), and liver function were performed after initiation of cART. Factors associated with time to undetectable HBV DNA load were explored.


A total of 366 patients were included according to cART history: Group 1, 3TC as the only anti-HBV therapy (n = 73); Group 2, TDF-containing cART as initial therapy (n = 127); and Group 3, switch of 3TC-based to TDF-containing cART (n = 166). At year 5, HBV suppression was achieved in 77.8%, 95.7%, and 95.7% of Groups 1, 2 and 3, respectively. In multivariate Cox regression analysis, TDF ( ± 3TC or FTC) but not 3TC alone as initial anti-HBV therapy was significantly associated with HBV suppression (adjusted hazard ratio [aHR] 2.635; 95% CI 1.720–4.037), while HBeAg positivity at baseline was associated with failure to achieve HBV suppression (aHR 0.293; 95% CI 0.178–0.482). Loss of HBsAg occurred in 15 patients (4.1%), with 7 (1.9%) seroconversion to anti-HBs positivity, while HBeAg seroconversion occurred in 11 (16.9%) of 65 HBeAg-positive patients.


TDF-containing cART achieved durable HBV viral suppression in HIV/HBV-coinfected patients and HBeAg positivity at baseline was associated with failure to achieve HBV suppression despite long-term TDF-containing cART.


Chronic hepatic complications Liver fibrosis Lamivudine Emtricitabine Tenofovir Nucleotide reverse-transcriptase inhibitor 


Compliance with ethical standards

Conflict of interest

C.-C. H. has received research support from Gilead Sciences, Merck, and ViiV and speaker honoraria from Gilead Sciences and ViiV, and served on the advisory boards for Gilead Sciences and ViiV. Yu-Shan Huang, Hsin-Yun Sun, Sui-Yuan Chang, Yu-Chung Chuang, Aristine Cheng, Sung-Hsi Huang, Yi-Chia Huang, Guan-Jhou Chen, Kuan-Yin Lin, Yi-Ching Su, Wen-Chun Liu have no conflicts of interest.

Ethical approval

The study was approved by the NTUH Research Ethics Committee (registration number, NTUH-201201028RIB).

Informed consent

The written or oral informed consent was waived.

Supplementary material

12072_2019_9953_MOESM1_ESM.docx (20 kb)
Supplementary file1 (DOCX 20 kb)


  1. 1.
    Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921–6.CrossRefGoogle Scholar
  2. 2.
    Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319(17):1802–13.CrossRefGoogle Scholar
  3. 3.
    Nikolopoulos GK, Paraskevis D, Psichogiou M, Hatzakis A. HBV-DNA levels predict overall mortality in HIV/HBV coinfected individuals. J Med Virol. 2016;88(3):466–73.CrossRefGoogle Scholar
  4. 4.
    Sheng WH, Kao JH, Chen PJ, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;45(9):1221–9.CrossRefGoogle Scholar
  5. 5.
    Dharan NJ, Neuhaus J, Rockstroh JK, et al. Benefit of early versus deferred antiretroviral therapy on progression of liver fibrosis among people with HIV in the START randomized trial. Hepatology. 2019;69(3):1135–50.CrossRefGoogle Scholar
  6. 6.
    Sun HY, Sheng WH, Tsai MS, Lee KY, Chang SY, Hung CC. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review. World J Gastroenterol. 2014;20(40):14598–614.CrossRefGoogle Scholar
  7. 7.
    Panel on Antiretroviral Guidelines for Adults and Adolescents (2018) Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. Accessed 26 May 2019.
  8. 8.
    Chen GF, Wang C, Lau G. Treatment of chronic hepatitis B infection-2017. Liver Int. 2017;37(Suppl 1):59–66.CrossRefGoogle Scholar
  9. 9.
    Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.CrossRefGoogle Scholar
  10. 10.
    Kumar S, Tamura K, Jakobsen IB, Nei M. MEGA2: molecular evolutionary genetics analysis software. Bioinformatics. 2001;17(12):1244–5.CrossRefGoogle Scholar
  11. 11.
    Kosi L, Reiberger T, Payer BA, et al. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. J Viral Hepat. 2012;19(11):801–10.CrossRefGoogle Scholar
  12. 12.
    Thio CL, Smeaton L, Hollabaugh K, et al. Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. AIDS. 2015;29(10):1173–82.CrossRefGoogle Scholar
  13. 13.
    Kang M, Hollabaugh K, Pham V, et al. Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort. J Acquir Immune Defic Syndr. 2014;66(2):172–80.Google Scholar
  14. 14.
    de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology. 2010;139(6):1934–41.CrossRefGoogle Scholar
  15. 15.
    Luo A, Jiang X, Ren H. Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis. Virol J. 2018;15(1):139.CrossRefGoogle Scholar
  16. 16.
    Tsai WC, Hsu WT, Liu WD, et al. Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection. Liver Int. 2019. Scholar
  17. 17.
    Huang YS, Chang SY, Sheng WH, et al. Virological response to tenofovir disoproxil fumarate in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection in an area hyperendemic for hepatitis B virus infection. PLoS ONE. 2016;11(12):e0169228.CrossRefGoogle Scholar
  18. 18.
    Bihl F, Martinetti G, Wandeler G, et al. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. BMC Gastroenterol. 2015;15:79.CrossRefGoogle Scholar
  19. 19.
    Hafkin JS, Osborn MK, Localio AR, et al. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. J Viral Hepat. 2014;21(4):288–96.CrossRefGoogle Scholar
  20. 20.
    Price H, Dunn D, Pillay D, et al. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS ONE. 2013;8(7):e68152.CrossRefGoogle Scholar
  21. 21.
    Audsley J, Bent SJ, Littlejohn M, et al. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. AIDS. 2016;30(10):1597–606.CrossRefGoogle Scholar
  22. 22.
    Matthews GV, Seaberg EC, Avihingsanon A, et al. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis. 2013;56(9):e87–94.CrossRefGoogle Scholar
  23. 23.
    Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59(2):434–42.CrossRefGoogle Scholar
  24. 24.
    Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology. 2011;53(6):1854–63.CrossRefGoogle Scholar
  25. 25.
    Boyd A, Gozlan J, Maylin S, et al. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications. Hepatology. 2014;60(2):497–507.CrossRefGoogle Scholar
  26. 26.
    Liu Y, Corsa AC, Buti M, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2017;24(1):68–74.CrossRefGoogle Scholar
  27. 27.
    Boyd A, Maylin S, Gozlan J, et al. Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV. Liver Int. 2015;35(3):795–804.CrossRefGoogle Scholar
  28. 28.
    Lin CL, Kao JH. Perspectives and control of hepatitis B virus infection in Taiwan. J Formos Med Assoc. 2015;114(10):901–9.CrossRefGoogle Scholar
  29. 29.
    Agarwal K, Brunetto M, Seto WK, et al (2018) 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 68(4):672–681Google Scholar
  30. 30.
    Gallant J, Brunetta J, Crofoot G, et al. Brief report: efficacy and safety of switching to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-1/Hepatitis B-coinfected adults. J Acquir Immune Defic Syndr. 2016;73(3):294–8.CrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2019

Authors and Affiliations

  • Yu-Shan Huang
    • 1
  • Hsin-Yun Sun
    • 1
  • Sui-Yuan Chang
    • 2
    • 3
  • Yu-Chung Chuang
    • 1
  • Aristine Cheng
    • 1
  • Sung-Hsi Huang
    • 4
    • 5
  • Yi-Chia Huang
    • 4
  • Guan-Jhou Chen
    • 6
  • Kuan-Yin Lin
    • 7
  • Yi-Ching Su
    • 1
  • Wen-Chun Liu
    • 1
  • Chien-Ching Hung
    • 1
    • 5
    • 8
    • 9
    Email author
  1. 1.Department of Internal MedicineNational Taiwan University Hospital and National Taiwan University College of MedicineTaipeiTaiwan
  2. 2.Department of Clinical Laboratory Sciences and Medical BiotechnologyNational Taiwan University College of MedicineTaipeiTaiwan
  3. 3.Department of Laboratory MedicineNational Taiwan University Hospital and National Taiwan University College of MedicineTaipeiTaiwan
  4. 4.Department of Internal MedicineNational Taiwan University Hospital Hsin-Chu BranchHsin-ChuTaiwan
  5. 5.Department of Tropical Medicine and ParasitologyNational Taiwan University College of MedicineTaipeiTaiwan
  6. 6.Department of Internal MedicineNational Taiwan University Hospital Yun-Lin BranchYun-Lin CountyTaiwan
  7. 7.Department of MedicineNational Taiwan University Hospital Jin-Shan BranchNew Taipei CityTaiwan
  8. 8.Department of Medical ResearchChina Medical University HospitalTaichungTaiwan
  9. 9.China Medical UniversityTaichungTaiwan

Personalised recommendations